Chauhan_2019_Arch.Pharm.(Weinheim)__e1900029

Reference

Title : Design, synthesis, biological evaluation, and molecular modeling studies of rhodanine derivatives as pancreatic lipase inhibitors - Chauhan_2019_Arch.Pharm.(Weinheim)__e1900029
Author(s) : Chauhan D , George G , Sridhar SNC , Bhatia R , Paul AT , Monga V
Ref : Arch Pharm (Weinheim) , :e1900029 , 2019
Abstract :

A series of rhodanine-3-acetic acid derivatives were synthesized via Knoevenagel condensation of rhodanine-3-acetic acid with various substituted aromatic aldehydes. The synthesized derivatives were screened in vitro for understanding the inhibitory potential towards pancreatic lipase (PL), a key enzyme responsible for the digestion of dietary fats. Derivative 8f exhibited a potential inhibitory activity towards PL (IC50 = 5.16 microM), comparable to that of the standard drug, orlistat (0.99 microM). An increase in the density of the aromatic ring resulted in potential PL inhibition. The enzyme kinetics of 8f exhibited a reversible competitive-type inhibition, similar to that of orlistat. Derivative 8f exhibited a MolDock score of -125.19 kcal/mol in docking studies, and the results were in accordance with their PL inhibitory potential. Furthermore, the reactive carbonyl group of 8f existed at a distance adjacent to Ser152 ( approximately 3 A) similar to that of orlistat. Molecular dynamics simulation (10 ns) of the 8f-PL complex revealed a stable binding conformation of 8f in the active site of PL (maximum root mean square displacement of approximately 2.25 A). The present study identified novel rhodanine-3-acetic acid derivatives with promising PL inhibitory potential, and further lead optimization might result in potent PL inhibitors.

PubMedSearch : Chauhan_2019_Arch.Pharm.(Weinheim)__e1900029
PubMedID: 31407389

Related information

Citations formats

Chauhan D, George G, Sridhar SNC, Bhatia R, Paul AT, Monga V (2019)
Design, synthesis, biological evaluation, and molecular modeling studies of rhodanine derivatives as pancreatic lipase inhibitors
Arch Pharm (Weinheim) :e1900029

Chauhan D, George G, Sridhar SNC, Bhatia R, Paul AT, Monga V (2019)
Arch Pharm (Weinheim) :e1900029